Serum levels of transforming growth factor-β1 in patients with mild psoriasis vulgaris and effect of treatment with biological drugs

Clinical and Experimental Dermatology

Volumn 34, Issue 5, 2009, Pages 582-586

  Kallimanis, P G ^a   Xenos, K ^a   Markantonis, S L ^a,b   Stavropoulos, P ^a   Margaroni, G ^a   Katsambas, A ^a   Avgerinou, G ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; EFALIZUMAB; ETANERCEPT; TRANSFORMING GROWTH FACTOR BETA1;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOWN REGULATION; DRUG MONITORING; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSORIASIS VULGARIS; SCORING SYSTEM; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; TRANSFORMING GROWTH FACTOR BETA1; TREATMENT OUTCOME; YOUNG ADULT;

EID: 66449108000     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2008.03026.x     Document Type: Article

References (24)

1. Lebwohl M. Psoriasis. Lancet 2003 361 : 1197 204.
2. Schafer T. Epidemiology of psoriasis. Dermatol 2006 212 : 327 37.
3. Krueger G, Ellis CN. Psoriasis-recent advances in understanding its pathgenesis and treatment. J Am Acad Dermatol 2005 53 : S94 100.
4. Nickoloff BJ. The cytokine network in psoriasis. Arch Dermatol 1991 127 : 871 84.
5. Bonifati C, Ameglio F. Cytokines in psoriasis. Int J Dermatol 1999 38 : 241 51.
6. Jacob SE, Nassiri M, Kerdela FA et al. Simultaneus measurement of multiple Th1 and Th2 serum cytokines in psoriasis and correlation with disease severity. Mediators Inflamm 2003 12 : 309 13.
7. Arican O, Aral M, Sasmaz S et al. Serum levels of TNF-α, IFN-γ, IL-6,IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm 2005 5 : 273 9.
8. Flisiak I, Chodynicka B, Porebski P et al. Association between psoriasis severity and TGF-β1 and TGF-β2 in plasma and scales from psoriatic lesions. Cytokine 2002 19 : 121 5.
9. Bonifati C, Carduci M, Mussi A et al. The levels of transforming growth factor-β1 are increased in the serum of patients and correlate with disease severity. Eur J Dermatol 1996 6 : 486 90.
10. Flisiak I, Porebski P, Flisiak R et al. Plasma TGF-β1 as a biomarker of psoriasis activity and treatment efficacy. Biomarkers 2003 8 : 437 43.
11. Lawrence DA. Transforming growth factor-beta: general review. Eur Cytokine Netw 1996 7 : 363 74.
12. Letterio JJ, Roberts AB. Regulation of immune responses by TGF-b. Annu Rev Immunol 1998 16 : 137 61.
13. Sporn MB, Roberts AB. Autocrine secretion-10 years later. Ann Intern Med 1992 117 : 408 14.
14. Shipley GD, Piltelkow MR, Wille JJ et al. Reversible inhibition of normal human prokeratinocyte proliferation by type beta transforming growth factor-growth inhibitor in serum-free medium. Cancer Res 1986 46 : 2068 71.
15. Wahl SM, McCarteney-Francis N, Mergenhagen SE. Inflammatory and immunomodulatory roles of TGF-β. Immunol Today 1989 10 : 258 61.
16. Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978 157 : 238 44.
17. Nockowski P, Szepietowski JC, Ziarkiewicz M et al. Serum concentrations of TGF-β1 in patients with psoriasis vulgaris. Acta Dermatovenerol Croat 2004 12 : 2 6.
18. Border WA, Ruoslahti E. Transforming growth factor-beta in disease: the dark side of tissue repair. J Clin Invest 1992 90 : 1 7.
19. Leonardi CL. Efalizumab: an overview. J Am Acad Dermatol 2003 49 : S98 104.
20. Goffe B, Cather JC. Etanarcept: an overview. J Am Acad Dermatol 2003 49 : S105 11.
21. Schottelius AJG, Moldawer LL, Dinarello CA et al. Biology of tumor necrosis factor-α, implications for psoriasis. Exp Dermatol 2004 13 : 193 222. (Pubitemid 38618076)
22. Cai JP, Falanga V, Taylor JR et al. Transforming growth factor-β1 receptor binding and function are decreased in psoriatic dermal endothelium. J Invest Dermatol 1996 106 : 225 31.
23. Leivo T, Leivo I, Kariniemi AL et al. Down-regulation of transforming growth factor-β1 receptors I and II is seen in lesional but not in non-lesional psoriatic epidermis. Br J Dermatol 1998 138 : 57 62. (Pubitemid 28077938)
24. Wahl SM. Transforming growth factor-β1 in inflammation: a cause and a cure. J Clin Immunol 1992 12 : 61 74.